Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Mallinckrodt
Baxter
Deloitte
Daiichi Sankyo
Accenture
UBS
Argus Health
Healthtrust
Teva

Generated: February 24, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,973,040

« Back to Dashboard

Which drugs does patent 7,973,040 protect, and when does it expire?

Patent 7,973,040 protects ZEPATIER and is included in one NDA.

This patent has forty-four patent family members in thirty-six countries.
Summary for Patent: 7,973,040
Title:Macrocyclic quinoxaline compounds as HCV NS3 protease inhibitors
Abstract: The present invention relates to macrocyclic a compound of formula (I) and its use as inhibitors of the hepatitis C virus (HCV) NS3 protease, and in treating or preventing HCV infections. ##STR00001##
Inventor(s): Harper; Steven (Rome, IT), Summa; Vincenzo (Rome, IT), Liverton; Nigel J. (Harleysville, PA), McCauley; John A. (Maple Glen, PA)
Assignee: Merck Sharp & Dohme Corp. (Rahway, NJ) Istituto di Ricerche di Biologia Molecolare P. Angeletti SpA (Rome, IT)
Application Number:12/504,955
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 7,973,040

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Merck Sharp Dohme ZEPATIER elbasvir; grazoprevir TABLET;ORAL 208261-001 Jan 28, 2016 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y TREATMENT OF PATIENTS INFECTED WITH HEPATITIS C VIRUS ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,973,040

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,080,654 Macrocyclic quinoxaline compounds as HCV NS3 protease inhibitors ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,973,040

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Serbia 52534 ➤ Try a Free Trial
Portugal 2540350 ➤ Try a Free Trial
Portugal 2310095 ➤ Try a Free Trial
Peru 02122011 ➤ Try a Free Trial
New Zealand 590638 ➤ Try a Free Trial
Norway 2017004 ➤ Try a Free Trial
Netherlands 300857 ➤ Try a Free Trial
Malaysia 152070 ➤ Try a Free Trial
Mexico 2011000826 ➤ Try a Free Trial
Morocco 32502 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Johnson and Johnson
Argus Health
Julphar
Farmers Insurance
Moodys
UBS
Merck
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot